Lauren Riker - Jun 14, 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Senior Vice President, Finance
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jun 14, 2023
Transactions value $
-$244,606
Form type
4
Date filed
6/16/2023, 05:39 PM
Previous filing
Jun 7, 2023
Next filing
Jul 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Award $0 +10K +52.49% $0.00 29.1K Jun 14, 2023 Direct F1
transaction PCRX Common Stock Sale -$22K -586 -2.02% $37.47 28.5K Jun 14, 2023 Direct F2, F3
transaction PCRX Common Stock Sale -$222K -5.77K -20.28% $38.52 22.7K Jun 14, 2023 Direct F2, F4
transaction PCRX Common Stock Sale -$273 -7 -0.03% $39.01 22.7K Jun 14, 2023 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +25K $0.00 25K Jun 14, 2023 Common Stock 25K $38.74 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.975 to $37.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 5.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.000 to $38.995, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.000 to $39.010, inclusive.
F6 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.